Sarasota Memorial reported that 75% of lung cancers diagnosed through its early detection program were found at Stage I or II ...

Illumina and D3b, have announced a new data partnership aimed at accelerating research in pediatric cancer and rare disease, ...

Partner Therapeutics has submitted a supplemental Biologics License Application to the U.S. FDA for BIZENGRI, ...

BioNTech and DualityBio reported encouraging Phase 2 results for trastuzumab pamirtecan, an investigational HER2-targeted ...

Researchers at MD Anderson identified DPY30 as a key biomarker and epigenetic regulator that enables pancreatic tumors to ...

FDA has accepted and granted Priority Review to the biologics license application for ifinatamab deruxtecan in adults with ...

A new study led by UCL researchers suggests that making cancer cells more visible to the immune system could broaden the ...

GSK has reported encouraging early clinical data from the global phase I BEHOLD-1 trial of mocertatug rezetecan, a ...

Researchers from MD Anderson identified DHODH as a key metabolic driver of radiotherapy resistance in lung cancer. Radiation ...

Neladalkib has been submitted for FDA review in TKI pre-treated advanced ALK-positive NSCLC, based on data from the global ...